Neuron23 Incis A Clinical Stage Biotechnology Company Based In South San Franciscocaliforniafounded In Late 2018The Company Specializes In Developing Precision Medicines For Neurological And Immunological Diseases By Utilizing Advanced Data Sciencehuman Geneticsand Machine Learningunder The Leadership Of Ceo Nancy Staglianoneuron23 Focuses On Addressing Diseases Like Parkinsonae S And Alzheimerae S By Targeting Specific Genetic Drivers The Companyae S Lead Program Involves Lrrk2 Inhibitorswhich Are Small Molecule Therapies Aimed At Slowing Or Halting The Progression Of Parkinsonae S Disease In Patients With Lrrk2 Mutationsneuron23 Is Also Collaborating With Qiagen To Create A Next Generation Sequencing Based Companion Diagnostic To Identify Patients Eligible For These Targeted Therapiesadditionallyresearch On Tyrosine Kinase 2Tyk2Has Been Publishedindicating Potential Therapeutic Applications In Neuroimmunologyneuron23 Combines Ai And Machine Learning With A Focus On Precision Medicine To Enhance Treatment Efficacy For Genetically Defined Patient Subgroups
No conferences found for this company.
| Company Name | Neuron23 Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
